Cartalax vs Glutathione
Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression
Your body's master antioxidant — a tiny three-part protein that shields your cells and helps clear out toxins.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Cartalax
200–200 mcg
Glutathione
200–200 mg
Frequency
Cartalax
Once daily
Glutathione
Once daily by mouth; IV and inhaled protocols are typically given 1–3 times per week
Administration
Cartalax
Oral (capsule)
Glutathione
Subcutaneous injection
Cycle length
Cartalax
12+ weeks
Glutathione
Often used continuously; studied by mouth for up to 6 months
Onset speed
Cartalax
Gradual (3-4 weeks)
Glutathione
Builds gradually — blood and tissue levels rise over weeks of steady use, while IV and inhaled forms act faster
Evidence level
Cartalax
Moderate human trials (Phase 1-2)
Glutathione
Moderate human trials (Phase 1-2)
Benefit ratings
Anti-Aging
Healing & Recovery
Hormone Support
Antioxidant defense
Detoxification support
Immune support
Brain/neuroprotection interest
Compound specifications
Cartalax
Molecular formula
C12H19N3O8
Molecular weight
333.3 g/mol
Half-life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids
Bioavailability
Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)
CAS number
Not yet registered (research compound)
Glutathione
Molecular formula
C10H17N3O6S
Molecular weight
307.33 g/mol
Half-life
Very short in blood — roughly 2 to 10 minutes as intact glutathione; tissue pools turn over more slowly
Bioavailability
Low by mouth — intact glutathione is largely broken down in the gut by gamma-glutamyl transpeptidase; liposomal, intranasal, IV and inhaled routes bypass this
CAS number
70-18-8
Dosing compared
Cartalax
Subcutaneous
200 mcg
Once daily · 10-day cycles, repeated periodically
Cartalax has only lab and cell-culture research, so there is no trial-set human dose. In practice it is commonly given as 200 mcg daily in short 10-day cycles, matching how other Khavinson short peptides are used [3][4].
Glutathione
Subcutaneous
100 mg per injection
2–3 times per week · Ongoing, as directed
Delivered under the skin, bypassing gut breakdown like the intramuscular route shown effective in a controlled trial (600 mg IM every other day) [7]. Subcutaneous-specific dosing is drawn from clinical practice rather than published trials, so start at the lower end to gauge tolerance. Most protocols use a 0.5–1 mL injection volume.
200 mg per injection (up to ~600 mg per week total)
2–3 times per week · Ongoing, as directed
The most common subcutaneous range used in practice. It mirrors the systemic delivery of the controlled intramuscular protocol [7]; subcutaneous-specific numbers come from clinical use rather than trials. Rotate injection sites (abdomen, thigh) and use sterile, single-use supplies.
Oral
250 mg per day
Once daily · Up to 6 months
The lower dose from the 6-month oral trial in 54 healthy adults; it raised glutathione stores roughly 17-29% in blood versus baseline, and levels returned to baseline within a month of stopping [2].
1,000 mg per day
Once daily · Up to 6 months
The higher dose in the same 54-person trial raised blood glutathione about 30-35% versus baseline and more than doubled natural-killer immune-cell activity versus placebo by 3 months [2]. In a separate 12-person pilot with no placebo arm, liposomal glutathione at 500-1,000 mg per day raised whole-blood glutathione up to 40% versus baseline within 2 weeks [12].
Intravenous
1,400 mg per infusion
3 times per week · 4 weeks (as studied)
Clinic-administered. In the 4-week Parkinson's trial (21 people: 11 on IV glutathione 1,400 mg three times weekly, 10 on placebo), reported adverse events were similar in the two groups, no one withdrew because of them, and the treatment did not show a statistically significant benefit over placebo on symptom scores [1]. Must be given by a healthcare professional.
Intranasal
100-200 mg per dose
3 times daily (as studied) · Up to 3 months (as studied)
Trial dosing in Parkinson's: 100 or 200 mg three times daily for 3 months in 45 people — symptoms improved in every group including placebo, neither dose beat placebo, and one of the 15 people in the 200 mg arm developed cardiomyopathy [10]. An earlier 30-person trial of 300-600 mg per day divided found adverse events no more frequent than placebo [9]. A single 200 mg dose raised brain glutathione in 15 people (about a 269% rise in the glutathione-to-creatine signal at 45 minutes versus baseline) [3]. Uses a compounded nasal spray; trial samples lost potency to 72-81% of label within 4-6 weeks [3].
Intramuscular
600 mg per injection
Every other day · 2 months (as studied)
This is the dose used in a placebo-controlled, double-blind trial, where 600 mg intramuscular every other day for 2 months improved sperm motility and structure [7]. Given by a healthcare professional or trained self-injector.
Topical
2% oxidized glutathione (GSSG) lotion
Twice daily · 10 weeks (as studied)
Applied to the skin, not injected. In a placebo-controlled trial, a 2% oxidized-glutathione lotion twice daily for 10 weeks lightened skin tone and improved the skin barrier [8]. Topical use acts locally on the skin and does not meaningfully raise whole-body glutathione.
Best suited for
Cartalax
Cartilage regeneration and protection in age-related osteoarthritis
Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Connective tissue repair and maintenance in aging individuals
Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Glutathione
Everyday antioxidant support
Raising your body's own glutathione helps mop up free radicals — the unstable molecules behind cell wear-and-tear. Six months of daily oral dosing measurably increased body stores [2].
Liver and detox support
Glutathione tags toxins and drug byproducts so your liver can clear them out through the glutathione-S-transferase pathway [4].
Immune support
In the 6-month oral trial, the higher dose more than doubled the activity of natural killer cells, a front-line immune defender [2].
Brain-delivery research (Parkinson's)
Getting glutathione into the brain through the nose or a vein has been studied in Parkinson's disease, where it was well tolerated and reached brain tissue [1][3].
Side effects
Cartalax
Common
- Mild injection site reaction
- Mild GI discomfort
- Mild fatigue
- Transient joint stiffness
Uncommon
- Temporary increase in joint discomfort
Serious
- No documented serious adverse effects
Glutathione
Common
- Generally well tolerated
- Unpleasant smell or taste
Uncommon
- Mild stomach upset, bloating or loose stools
- Transient cough
Serious
- Bronchospasm (airway tightening) in asthma
Safety & evidence
Cartalax
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active joint infection — treat infection before initiating peptide bioregulator therapy
- Malignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated
Glutathione
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Sold as a dietary supplement; not FDA-approved as a drug. IV and inhaled uses are off-label/compounded.
Safety overview
Glutathione has a reassuring safety record in trials, but the trials are small. In the 6-month oral trial (54 healthy adults taking 250 or 1,000 mg a day), blood glutathione rose and returned to baseline after a 1-month washout [2]. In the IV Parkinson's trial (21 people: 11 on 1,400 mg three times a week, 10 on placebo), reported adverse events were similar in the two groups and no one withdrew because of them [1]. Intranasal glutathione was tolerated over 3 months in a 30-person trial (placebo, 300 or 600 mg per day) with no substantial difference in adverse events between groups [9]; in the follow-up 45-person trial, one of the 15 people on the highest dose (200 mg three times daily) developed cardiomyopathy — a weakening of the heart muscle [10]. The clearest warning is for the inhaled form: in 8 people with mild asthma, nebulized glutathione (600 mg) dropped lung function (FEV1) 19% versus 1% after placebo, with coughing in 4 of 8 and breathlessness in 3 of 8 — the researchers attributed the airway narrowing to sulfite formation [5].
Contraindications
- Known allergy to glutathione or a product ingredient
- Asthma — inhaled/nebulized forms can trigger airway tightening, especially in sulfite-sensitive people
Which is right for you?
Choose Cartalax if...
- Cartilage regeneration and protection in age-related osteoarthritis
- Connective tissue repair and maintenance in aging individuals
- Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
- Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Choose Glutathione if...
- Everyday antioxidant and detox support
- Liver and immune support
- Healthy aging
- Adjunct interest in Parkinson's disease